Increasing awareness about the availability of these devices along with the launch of new devices that address many unmet needs contribute to the growth.
Zacks Investment Research upgraded shares of Axonics (NASDAQ:AXNX – Get Rating) from a sell rating to a hold rating in a research note published on Friday morning, Zacks.com reports. According to Zacks, “Axonics Modulation Technologies Inc. is focused on development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction […]